An Australian medical cannabis company will see its products distributed in the United Kingdom thanks to its partner.

On Thursday (November 21), Zelda Therapeutics (ASX:ZLD,OTCQB:ZLDAF) confirmed a new non-exclusive agreement with Health House Holdings to start the distribution for its HOPE line of medical cannabis products in the UK market.

“Health House has an extensive network of medicinal healthcare professionals that support and assist doctors to gain with information relating to Zelda-products,” the Australian firm told investors.

Zelda Managing Director Richard Hopkins said the deal represents a critical advancement for his company in the lead-up to the launch of other medical cannabis products in 2020.

Hopkins and fellow Zelda Director Jason Peterson together own a combined 25 percent stake in Health House.

Zelda is set to obtain the full rights to the HOPE line of products as part of its merger plan with privately held Ilera Therapeutics.

“We’re excited by the potential of their Insomnia formulation as there is a significant market for products that can improve sleep,” said Tony Samios, CEO of Health House. “We’re also looking forward to distributing HOPE which has successfully established itself in the American market and has the potential to address a major unmet need for medicines targeting autism.”

Shares of Zelda bumped up 1.52 percent after the distribution announcement during Thursday’s trading session to AU$0.06.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Ensuring estoraTMpatients have seamless access to their high-quality medical cannabis products

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announce that its subsidiary Pineapple Express Delivery Inc. (“Pineapple Express Delivery” or “PED”), a leading logistics technology company offering compliant and secure delivery of controlled substances and regulated products, has partnered with CannTrust Inc. to bring same-day and next-day delivery to estoraTM medical cannabis patients in Ontario

Keep reading... Show less

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less